Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer
Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Unmet Needs and Future Perspectives on Colorectal Cancer
A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in colorectal cancer.
Trials Focused on ctDNA in Colorectal Cancer
An expert panel discusses clinical trials focused on circulating tumor DNA in guiding treatment selection in colorectal cancer.
SUNLIGHT and FRESCO-2 Trials in Refractory Colorectal Cancer
An overview of the SUNLIGHT and FRESCO-2 studies in the refractory colorectal cancer space.
Colorectal Cancer: Insights on ctDNA and Retesting for HER2 Expression
A panel of experts discuss the role of ctDNA and their practices for retesting HER2 expression to guide treatment for colorectal cancer.
T-DXd in Patients With HER2+ Metastatic Colorectal Cancer
A comprehensive overview of trastuzumab deruxtecan (T-DXd) as a treatment for patients with HER2+ metastatic colorectal cancer.
Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis
Arshiya Mariam, BS, and colleagues report the findings of a large meta-analysis assessing the ability of various biomarkers to predict responses to immune checkpoint inhibition.
Patient Profile: A 40-Year-Old Woman With Colorectal Cancer
Experts on colorectal cancer present the case of a 40-year-old woman with CRC, who receives later-line treatment with trastuzumab deruxtecan, and share their initial thoughts.
Metastatic CRC: Role of ctDNA in Treatment Selection
Insights on the role of circulating tumor DNA in treatment selection for patients with metastatic colorectal cancer.
PARADIGM Trial: Recent Data on EGFR-Targeting Therapy for mCRC
Arvind Dasari, MD, MS, reviews the PARADIGM study on EGFR-targeting therapy in metastatic colorectal cancer.
Patient Profile: A 47-Year-Old Woman With HER2+ CRC and Early Disease Progression
Expert oncologists present the case of a 47-year-old woman with colorectal cancer and early disease progression, and discuss treatment options with the ongoing MOUNTAINEER-03 study.
MOUNTAINEER: Tucatinib Plus Trastuzumab in HER2+ Metastatic Colorectal Cancer
Experts on HER2+ metastatic colorectal cancer review the MOUNTAINEER study on tucatinib plus trastuzumab.
Treatment Landscape for HER2+ Metastatic Colorectal Cancer
An overview of the treatment landscape for HER2+ metastatic colorectal cancer and recent updates to the NCCN Guidelines.
Overview of HER2+ Metastatic Colorectal Cancer
Expert oncologists discuss the landscape surrounding HER2+ metastatic CRC, including recommendations for biomarker testing and an overview of scoring criteria.
Patient Profile: A 46-Year-Old Woman With HER2+ Metastatic Colorectal Cancer
A panel of expert oncologists present the case of a 46-year-old woman with HER2+ metastatic colorectal cancer, who is treated with tucatinib in the second-line setting.
Shorter Time to Treatment Is Associated With Improved Survival in Rural Patients With Breast Cancer Despite Other Adverse Socioeconomic Factors
Minh-Tri Nguyen, MD, and colleagues investigate the association between time to treatment, socioeconomic status, and clinical outcomes among rural and urban patients with breast cancer.
Oncology Peer Review On-The-Go: Financial Conflicts of Interest Among Junior Faculty in Hematology and Oncology
Suneel D. Kamath, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on how financial conflicts of interest correlate with success of early-career academic oncologist.
Association of Financial Conflicts of Interest With Academic Productivity Among Junior Faculty in Hematology and Oncology
Conflicts of interest for junior faculty members were evaluated at top cancer centers by Suneel D. Kamath, MD, et al. to determine how financial conflicts of interest correlated with measures of academic career productivity.
